Non-invasive ventilation in Bronchiectasis

• Research type

  Research Study

• Full title

  A retrospective study of the efficacy of non-invasive ventilation in non-cystic fibrosis bronchiectasis

• IRAS ID

  288577

• Contact name

  Sriram Iyer

• Contact email

  sriram.iyer2@nhs.net

• Sponsor organisation

  Sheffield Teaching Hospitals

• Duration of Study in the UK

  0 years, 6 months, 30 days

• Research summary

  Bronchiectasis is a chronic respiratory disease characterized by irreversible dilation of cartilage-containing airways and distortion, inflammation, and mucous plugging of the bronchial tree.
  In some patients with non-CF bronchiectasis, specific treatment is directed to the underlying condition. In most patients, treatment is nonspecific and limited to chest physiotherapy to clear sputum and antibiotics to control the infection. Acute worsening and respiratory failure can lead to emergency admissions.
  Over the last few years, non-invasive ventilation (NIV) has been used successfully for treatment of acute respiratory failure (ARF) due to exacerbations in bronchiectasis. Many patients are using this on a longer term basis at home, not during exacerbations. There are no randomised control trials with data available that have shown mortality benefit, nor compared the specific parameters of bilevel modes of ventilation across various patient cohorts.
  Our objectives are to assess the effects of non‐invasive ventilation on survival, lung function, exacerbations and hospital admissions, and respiratory complications in non-CF bronchiectasis
  Eligible patients are those with a clinical diagnosis of bronchiectasis, at any stage of disease and with any clinical pattern of the condition.
  The data will be collected from patients using the following centres' databases:
  Sheffield Teaching Hospital NHS Foundation Trust
  Royal Brompton & Harefield NHS Foundation Trust

  The data will only be collected by staff from the department directly involved in the patient’s clinical care. It will be stored with a password protected secure data drive on the NHS platform at the participating sites. The data will be pseudo-anonymised and there will be no identifiable linking data for the patients in the study. The CI of the study will be the data controller, regulated by local research and development office.

• REC name

  N/A

• REC reference

  N/A